CClinicalTrials.gg
CompletedNCT05249985Updated Feb 16, 2024

Protein Supplementation and Neuromuscular Electrical Stimulation in Persons With SCI

An interventional study of NMES and Protein in Spinal Cord Injuries, sponsored by Loughborough University. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-16.

Sponsored by Loughborough University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The aim of this pilot study is to explore how body composition, circulating markers of metabolic health and skin integrity in persons with a spinal cord injury (SCI) are affected by 12 weeks of quadriceps neuromuscular electrical stimulation (NMES) resistance training. The novel element of this study is that one group will be given additional daily protein supplementation in addition to the NMES training (treatment group), whereas the other group will only perform the NMES training (control group). The investigators hypothesise that NMES in combination with protein results in larger improvements in the aforementioned outcomes compared with NMES alone.

Read the detailed description

A spinal cord injury (SCI) is a debilitating condition, with paralysis below the lesion level as one of the main hallmarks. As a result of paralysis, together with decreased levels of physical activity and impairment-specific co-morbidities such as autonomic dysfunction, persons with SCI have a markedly reduced muscle mass. Being the major site for glucose disposal, skeletal muscle is key for the maintenance of metabolic health, while it also helps with weight management by contributing to energy expenditure at rest. As such, effective strategies to restore muscle mass in persons with SCI are warranted and can have a significant impact on metabolic health and chronic disease risk in this population.

While resistance training is widely recognised as an effective intervention to increase muscle mass in able-bodied individuals, paralysis in the lower limbs of persons with SCI precludes the use of traditional resistance training in this population. NMES has been developed to overcome this barrier and allows persons with SCI to engage in resistance exercise. Notwithstanding the evidence supporting the use of NMES on its own, combined interventions may further enhance its potential to improve health and physical function. Indeed, in the more widely studied population of older adults, that is also at risk for sarcopenia (loss of skeletal muscle mass and strength), increasing daily protein intake enhances the efficacy of resistance training to increase muscle mass.

The primary objective of this study is to determine the impact of a 12-week intervention of NMES in combination with protein supplementation when compared with NMES alone on fat free mass in the legs. Secondary objectives are to investigate the impact of the intervention on 1) markers of cardiometabolic health, namely glucose tolerance and fasting plasma lipid concentrations, 2) resting metabolic rate, and 3) skin blood flow at the level of the sacrum in response to experimental pressure. Outcomes related to tertiary objectives include perceived quality of life, neuropathic pain, body image, sleep quality and spasms; as well as free-living energy balance, physical activity and feasibility outcomes related to recruitment, adherence and participant' experiences with the intervention. It is hypothesised that NMES in combination with protein results in larger improvements in the aforementioned outcomes compared with NMES alone.

02

Conditions studied

  • Spinal Cord Injuries

Keywords

  • Protein
  • NMES
03

In context

Spinal Cord Injuries

1,948 studies on the registry are indexed under Spinal Cord Injuries; 505 are open to participants now.

This study's enrollment of 30 is above the median of 24 across 1,566 interventional studies indexed under Spinal Cord Injuries.

Browse Spinal Cord Injuries studies →

Lead sponsor

Loughborough University is the lead sponsor of 71 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Motor complete spinal cord injury
  • Time since injury injury >1 year

Exclusion criteria

Exclusion Criteria:

  • Spinal cord injury below T10 vertebrae
  • Habitual protein intake exceeding 2g / kg body mass / day
  • Having used NMES resistance training once or more per week in the last six months
  • Lactose intolerant
  • Any disease or medication that means the participant should not exercise
  • Participation in a study involving ionising radiation in the previous 12 months
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    NMES plus protein supplementation

    Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps in addition to a daily protein supplement.

    Device: NMES · Dietary Supplement: Protein

  • Active comparator
    NMES

    Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps.

    Device: NMES

Interventions

  • DeviceNMES

    Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps.

  • Dietary supplementProtein

    Participants will consume a daily protein supplement

06

What researchers measure

Primary outcomes

  1. Change in bone mineral density

    Dual x-ray absorptiometry

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  2. Change in lean soft tissue mass

    Dual x-ray absorptiometry

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  3. Change in fat mass

    Dual x-ray absorptiometry

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

Secondary outcomes

  1. Change in glucose tolerance

    Oral glucose tolerance test

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  2. Change in insulin resistance

    Oral glucose tolerance test

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  3. Change in fasting plasma lipid concentrations

    Resting blood sample

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  4. Change in fasting circulating C-reactive protein

    Resting blood sample

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  5. Change in sacral skin blood flow

    Doppler flowmetry

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  6. Change in resting metabolic rate

    Expired air analysis

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

Other outcomes

  1. Change in blood pressure

    Automatic blood pressure cuff

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  2. Change in daily energy intake

    3 day food diary

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  3. Change in physical activity

    Wrist-worn accelerometer

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  4. Change in physical activity

    Leisure time physical activity questionnaire

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  5. Change in sleep efficiency and duration

    Wrist-worn accelerometer

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  6. Change in sleep quality

    Sleep Quality Scale (available answers include: rarely, sometimes, often, almost always)

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  7. Change in muscle spasticity

    The Spinal Cord Injury Spasticity Evaluation Tool

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  8. Change in mental health

    5-item Mental Health Inventory

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  9. Change in neuropathic pain

    Neuropathic Pain Questionnaire

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  10. Change in body image

    Body Image Satisfaction Questionnaire

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  11. Change in skinfold thickness

    Measured in millimetre

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  12. Height

    Measured in meters

    Time frame: Pre-intervention only

  13. Change in waist and hip circumference

    Measured in centimeters to provide a waist-to-hip ratio

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

  14. Change in body weight

    Measured in kilograms

    Time frame: Pre-intervention (baseline) and at 1 week post-12 week intervention

07

Study locations

1 site
  • Loughborough University
    Loughborough, Leicestershire LE113TU, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05249985
Lead sponsor
Loughborough University
Collaborators
McMaster University, Danone Nutricia
Responsible party
Professor Victoria Tolfrey (Professor of Applied Disability Sport Director of the Peter Harrison Centre for Disability Sport, Loughborough University) — Principal investigator
First posted
Feb 22, 2022
Start date
Apr 5, 2022
Primary completion
Jan 20, 2024
Completion
Feb 15, 2024
Last update
Feb 16, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion